Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP

Valneva SE VALN

7 fiscal years on record · EUR · FY2025 reported · SEC filings only
€174.7M
▲ 3.0% YoY
€-115.2M
€-57.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. It commercializes a portfolio of traveler vaccines composed of IXIARO, also marketed as JESPECT in Australia and New Zealand, DUKORAL, and IXCHIQ. IXIARO is indicated for the prevention of Japanese encephalitis in travelers and military personnel. DUKORAL is indicated for the prevention of cholera and, in Canada, Switzerland, New Zealand, and Thailand, for the prevention of diarrhea caused by LT-Enterotoxigenic Escherichia coli. IXCHIQ is indicated for active immunization for the prevention of disease caused by chikungunya virus and is marketed in Europe, Canada, Brazil, and the United Kingdom. It operates three manufacturing sites, augmented by contract manufacturing partners. Its Livingston, Scotland site supports multi-product manufacturing and employs approximately 140 staff. It has a commercial organization of approximately 60 employees for the distribution of its travel vaccines and third-party vaccines.

Written from the business description in Valneva SE's annual report to the U.S. Securities and Exchange Commission, filed 17 March 2026. Every sentence was checked against that document before publication.

Growth

EUR 174.7M
Revenue, FY2025 · full 7-year series below
Revenue €M Net income €M
FY2025 · Revenue 174.7 · Net income -115.2
150M300M-100M-200M
201920222025
Compound annual growth
−21.5%
+9.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +9.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−66 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -47.0% · Net -66.0%
2%4%6%-20%-40%-60%
201920222025
ROE
FY2021 · ROE -49.5%
-20%-40%
201920222025
Three returns, three denominators.
Return on equityNot available: we don't have a clean profit figure for this period.

Return on equity has no reading this year — return on capital employed, just below, still does: -24%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow €M
FY2025 · FCF -57.3
50M100M-100M-200M
201920222025

Total assetsEUR 398.8M
CashEUR 109.7M
Gross debtEUR 179.2M
Net debtEUR 69.5M
Current ratio2.38×

Net debt stands at 65% of equity.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative—not applicable◌not available in our data
VALN, 7-year financial record
Metric 2025202420232022202120202019
Revenue €B0.20.20.20.40.30.10.1
Operating income €B−0.10.0−0.1−0.1−0.1−0.1−0.0
EBITDA €B−0.10.0−0.1−0.1−0.0−0.0◌
Income tax €B0.00.00.0−0.00.0−0.00.0
Net income €B−0.1−0.0−0.1−0.1−0.1−0.1−0.0
Free cash flow €B−0.1−0.1−0.2−0.3−0.00.1−0.0
EPS, diluted €−0.68−0.08−0.73−1.24−0.75−0.71−0.02
Dividend / sh €◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %◌◌◌◌−49.5−51.9−0.6
Shares out B0.170.160.140.140.110.09◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image